Programs
CV6 Therapeutics is developing a pipeline of investigational therapies designed to enhance the activity of widely used treatments in cancer and inflammatory disease.
Our programs are built around a novel understanding of uracil-DNA metabolism and are designed to work in combination with existing standards of care, with the goal of enhancing therapeutic activity while preserving tolerability.
Scientific Focus
Our scientific focus centers on uracil-DNA metabolism, a previously underexplored therapeutic pathway of growing scientific interest. By developing small molecule therapies that selectively target this process, we aim to modulate abnormal cellular behavior through targeted therapeutic mechanisms. Our therapies are designed to integrate seamlessly with established treatments, modulating therapeutic activity and addressing mechanisms associated with resistance.
Oncology
CV6 is advancing investigational therapies for cancers where standard treatments remain essential but resistance remains a major clinical challenge.
Inflammatory Diseases
CV6 is applying the same scientific approach to inflammatory diseases, including rheumatoid arthritis, where significant unmet medical needs remain.
Pipeline
CV6 is building a pipeline of investigational therapies designed for combination use to enhance the activity of established treatments through novel therapeutic mechanisms.
Our lead oncology asset, CV6-168, is currently in Phase 1a clinical trials. Additional programs are advancing toward clinical development, extending the platform into additional therapeutic areas.